By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The development of portable, interactive, wirelessly connected, and patient-administered therapy-enabling electronic drug delivery systems (EDDS) is an intriguing topic that has the potential to lower healthcare costs. The insulin pump is the EDDS that is most frequently used and has the biggest market share worldwide.
The global electronic drug delivery system market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The global market for electronic drug delivery systems will be constrained by the high cost of the systems, the requirement for maintenance, the availability of substitute drug administration methods, and a lack of knowledge in low-income nations. Automated pumps may also carry a risk of incorrect dosing due to technological issues, which could result in negative medication reactions.
This can limit market expansion. A significant market opportunity has been generated for the companies as a result of technological improvements allowing accessible self-administration technologies, particularly in infusion pumps and autoinjectors that aid with large-volume and high-viscosity biologic medications.
The rising incidence of chronic illnesses including diabetes, asthma, and cardiovascular disease, as well as the development of smart medication delivery systems due to technology breakthroughs.
Adult diabetes management is being advanced by the approval of innovative medication formulations in infusion pumps. Additionally, wireless connections to smartphone apps are made possible for patients by smart wearable infusion pumps.
This makes it possible for medical personnel to monitor patient data and modify certain medicines in accordance with patient needs. Market expansion is anticipated as a result of the introduction of connected autoinjectors for the treatment of diabetes.
The main tools used in chronic diseases to give smaller doses are autoinjectors and electronic pumps. The need for electronic drug delivery systems has increased due to the aforementioned issues on a global scale.
In terms of electronic oral drug delivery, Medimetrics is a pioneer. The first intelligent oral drug delivery and monitoring capsule in the world was developed and put into use by the firm under the name IntelliCap. The IntelliCap system combines wireless real-time communication, controlled drug release, and patient monitoring.
When a medicine is administered at specific rates and locations along the GI system, it may be quickly and easily evaluated in vivo. A control station computer will display the data immediately after the capsule reports pH and temperature readings, which are typically taken every 10 seconds.
Qfinity is a brand-new reusable auto injector platform created by Jabil. Qfinity is a reusable, spring-driven device that can be used with a range of medications, including those with higher viscosities and bigger volumes. The disposable 1- and 2.25-ml cassettes used by the reusable injector have a viscosity target of 30cP.
The appealing handheld device will also be offered in a networked version with integrated electronics that securely communicate data to the patient and/or their care team through the Jabil Digital Health Platform while monitoring it.
EUDRATEC SoluFlow is a supplement to the oral drug delivery system solutions offered by Evonik Health Care, which also includes technology and services to enhance medication performance as well as oral excipients including EUDRAGIT functional polymers and the ready-to-fill functional capsules EUDRACAPTM.
The life sciences division of Evonik, Nutrition & Care, which seeks to enhance its market share of system solutions, includes Evonik Health Care. Evonik’s innovative technique makes it possible to use compounds that were previously thought to be insoluble, opening the door to a larger range of oral medications. They are eager to collaborate with consumers to create oral medications for longer, healthier lives.
Following its acquisition by Altaris Capital Partners, Kindeva Drug Delivery, formerly 3M Drug Delivery Systems, declared its establishment as an independent business.
Along with Altaris, 3M will keep a 17% minority stake in Kindeva as part of the deal. For its pharmaceutical and biotechnology clients, Kindeva is a top worldwide contract development and manufacturing organisation (CDMO) that specialises in finding solutions to challenging drug delivery problems.
Numerous development initiatives for COVID-19 vaccines, immunotherapies, osteoporosis treatments, and other challenging-to-deliver therapeutics currently make use of the company’s microneedle-based drug delivery platforms.
An official agreement has been reached between Halozyme Therapeutics, Inc. and Antares Pharma, Inc., according to which Halozyme will purchase Antares. The Boards of Directors of Antares and Halozyme both unanimously agreed to the deal.
By combining industry-leading expertise and drug delivery systems, this deal highlights the value of Antares’ very complementary company, offers shareholders attractive and certain value, and fosters growth and new opportunity.
Nemera, a global leader in the design, development, and production of drug delivery device solutions for the pharmaceutical, biotechnology, and generic industries, today announced a collaboration with Zollner Elektronik AG, one of the biggest global providers of electronic manufacturing services.
For the Healthcare & Life Sciences, Railway Technology, Aerospace & Defense, Automotive Technology, and many more industries, Zollner specialises in innovative mechatronics.
As Nemera’s preferred partner, Zollner will assist in the design, development, and production of electronic medicine delivery systems for both its own products and those held by clients. The high-volume wearable injectable device Symbioze from Nemera will serve as the foundation of this partnership. Zollner will be tasked by Nemera with developing the Symbioze’s electronics and software.
